Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Transpl Infect Dis ; 20(5): e12969, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30074295

ABSTRACT

BACKGROUND: BK polyomavirus (BKPyV)-associated nephropathy (BKPyVAN) is a consequence of BKPyV replication in the urinary tract in kidney transplant recipients (KTR). OBJECTIVES: The objectives were to determine the prevalence of BKPyV replication and BKPyVAN, risk factors associated to sustained viremia and BKPyVAN, and viremia cut-off that best predict the occurrence of sustained viremia and nephropathy in KTR of a single University Hospital Kidney Transplant Center. PATIENTS AND METHODS: All KTR undergoing transplantation from August 2010 to December 2011 were enrolled and monitored up to 2 years posttransplantation for BKPyV viruria by decoy cells shedding or polymerase chain reaction (PCR) and viremia by PCR. Kidney biopsy was indicated if sustained viremia (two or more viremia above 10 000 copies/mL) to confirm BKPyVAN diagnosis. RESULTS: In this study, 326 transplants were performed and 246 patients were included. Prevalence of viruria was 36.9%, viremia 22.3% and nephropathy 3.2%. Male gender was the only risk factor associated to sustained viremia or nephropathy. Cut-off value of viremia that best discriminates the progression to sustained viremia and to BKPyVAN was 37 488 and 44 956 copies/mL, respectively. CONCLUSIONS: Prevalence of viruria, viremia, and nephropathy were similar to those reported in literature but the cut-off value of viremia that best discriminates the risk of progression to nephropathy was greater than the value usually reported, which is 10 000 copies/mL.


Subject(s)
BK Virus/isolation & purification , Kidney Diseases/epidemiology , Polyomavirus Infections/epidemiology , Tumor Virus Infections/epidemiology , Viremia/diagnosis , Adolescent , Adult , Aged , BK Virus/physiology , Biopsy , DNA, Viral/isolation & purification , Disease Progression , Female , Graft Rejection/blood , Graft Rejection/epidemiology , Graft Rejection/pathology , Graft Rejection/virology , Humans , Immunosuppression Therapy/adverse effects , Immunosuppression Therapy/methods , Kidney/pathology , Kidney/virology , Kidney Diseases/diagnosis , Kidney Diseases/pathology , Kidney Diseases/virology , Kidney Transplantation/adverse effects , Male , Middle Aged , Patient Selection , Polyomavirus Infections/diagnosis , Polyomavirus Infections/pathology , Polyomavirus Infections/virology , Predictive Value of Tests , Prevalence , Prospective Studies , Risk Factors , Tumor Virus Infections/diagnosis , Tumor Virus Infections/pathology , Tumor Virus Infections/virology , Viremia/epidemiology , Viremia/virology , Young Adult
2.
Clin Transplant ; 28(11): 1234-43, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25142061

ABSTRACT

The purpose of this study was to sequentially monitor anti-HLA antibodies and correlate the results with antibody-mediated rejection (AMR), graft survival (GS), and graft function (GF). We collected sera from 111 kidney transplant recipients on transplant days 0, 7, 14, 30, 60, 90, 180, and 360 and analyzed PRA levels by ELISA. DSAs were analyzed by single-antigen beads in rejecting kidneys. At pre-transplant, 79.3% of the patients were non-sensitized (PRA = 0%) and 20.7% were sensitized (PRA > 1%). After transplant, patients were grouped by PRA profile: no anti-HLA antibodies pre- or post-transplant (group HLApre-/post-; n = 80); de novo anti-HLA antibodies post-transplant (group HLApre-/post+; n = 8); sensitized pre-transplant/increased PRA post-transplant (group HLApre+/post↑; n = 9); and sensitized pre-transplant/decreased PRA post-transplant (group HLApre+/post↓; n = 14). De novo anti-HLA antibodies were detected at 7-180 d. In sensitized patients, PRA levels changed within the first 30 d post-transplant. Incidence of AMR was higher in HLApre-/post+ and HLApre+/post↑ than in HLApre-/post-, and HLApre+/post↓ (p < 0.001) groups. One-yr death-censored GS was 36% in group HLApre+/post↑, compared with 98%, 88% and 100% in groups HLApre-/post-, HLApre-/post+, and HLApre+/post↓, respectively (p < 0.001). Excluding first-year graft losses, GF and GS were similar among the groups. In conclusion, post-transplant antibody monitoring can identify recipients at higher risk of AMR.


Subject(s)
Antibodies/blood , Graft Rejection/blood , Graft Survival , HLA Antigens/immunology , Kidney Failure, Chronic/blood , Kidney Transplantation , Adult , Cohort Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Kidney Failure, Chronic/surgery , Male , Middle Aged , Treatment Outcome
4.
J. bras. patol. med. lab ; 44(4): 293-304, ago. 2008. tab
Article in Portuguese | LILACS | ID: lil-504212

ABSTRACT

O transplante renal alcançou expressivos e crescentes índices de sucesso desde sua implantação, constituindo atualmente uma terapia substitutiva de larga escala. É cada vez mais freqüente o encontro de biópsias de enxerto renal na rotina dos laboratórios de patologia, cujos achados são os mais variados. Este artigo resulta da experiência dos membros do Clube do Rim (da Sociedade Brasileira de Patologia) e apresenta um panorama geral da patologia do transplante renal, enfatizando a atual classificação de Banff, com suas principais categorias e entidades de diagnóstico problemático.


Renal transplant has reached remarkable and growing rates of success since its introduction; nowadays it is a widely used replacement therapy. Renal allograft biopsies are increasingly more frequent in the routine of pathology laboratories, whose histological findings are varied. This paper results from the expertise of the members of the Kidney Club of Sociedade Brasileira de Patologia, and presents a general overview of renal allograft pathology, focusing on the current Banff classification, its main categories and cases of difficult diagnosis.


Subject(s)
Humans , Biopsy , Graft Rejection/classification , Graft Rejection/diagnosis , Graft Rejection/pathology , Kidney Transplantation/pathology
5.
Transplantation ; 84(11): 1391-8, 2007 Dec 15.
Article in English | MEDLINE | ID: mdl-18091514

ABSTRACT

BACKGROUND: Chronic rejection (CR) is an important cause of kidney graft loss. Some studies have suggested the role of antibodies mediating chronic graft dysfunction. In this context, C4d identification is an important tool to evaluate antibody-mediated rejection. METHOD: This is a retrospective study that analyzed 80 patients with histological diagnosis of chronic allograft nephropathy (CAN) according Banff 97 and no evidence of transplant glomerulopathy. These patients had renal biopsies available for C4d immunoperoxidase staining at the time of diagnosis. Cases were reclassified by the presence of C4d in peritubular capillaries. RESULTS: C4d was negative in 30 cases (37.5%) and positive in 50 (62.5%). C4d+ group had more female and highly sensitized patients (PRA) at transplant. All variables were similar between C4d- and C4d+ cases at diagnosis time, but more C4d+ patients presented proteinuria (>0.3 g/L). Patients were submitted to various immunosuppression regimens after the CAN diagnosis. Four years after the diagnosis, death-censored graft survival was 87% for C4d- and 50% for C4d+ (P=0.002). In the multivariate Cox regression analysis, C4d+, PRA>10%, and vascular intimal proliferation were the variables that present higher relative risk for graft loss. CONCLUSION: These data indicate that C4d positive chronic rejection is very common, associated with proteinuria, and has a poor outcome. A larger study is warranted to identify which immunosuppressive regimen may modify the poor course of this entity.


Subject(s)
Complement C4b/immunology , Complement C4b/metabolism , Graft Rejection/immunology , Graft Rejection/metabolism , Peptide Fragments/immunology , Peptide Fragments/metabolism , Adult , Chronic Disease , Female , Graft Rejection/pathology , Graft Survival/immunology , Humans , Kidney Diseases/immunology , Kidney Diseases/metabolism , Kidney Diseases/pathology , Kidney Transplantation/immunology , Male , Retrospective Studies , Risk Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...